Effects of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels Among Patients with Septic Shock: A Bayesian Reanalysis of the ANDROMEDA-SHOCK Trial.
A recent randomized controlled trial showed that a peripheral perfusion-guided resuscitation strategy was associated with lower mortality and less organ dysfunction when compared to lactate-guided resuscitation strategy in patients with septic shock, but the difference in the main outcome, 28-day mortality, did not reach the proposed statistical significance threshold(p=0.06). We tested different analytic methods to aid in the interpretation of these clinically relevant results. To reassess trial results using both Bayesian and frequentist frameworks. All patients recruited in the ANDROMEDA-Shock trial were included. Both a post-hoc Bayesian and mixed logistic regression approaches were performed.The first included 4 different priors (optimistic, neutral, null and pessimistic) for mortality endpoints. The probability of having a SOFA in the lower quartile at 72 hours was assessed using Bayesian networks. Through a Bayesian approach, the posterior probability that a peripheral perfusion-targeted resuscitation strategy is superior to lactate-targeted resuscitation at 28-days was above 90% for all priors; the probability of benefit at 90-days was also above 90% for all but the pessimistic prior. Using an optimistic prior, the Bayesian intervention odds ratio was 0.63 (95% credible interval 0.41-0.90) and 0.69 (95% credible interval 0.47-1.01) for 28-and 90-days mortality, respectively. The comparable frequentist odds ratios for 28-day and 90-day mortality were 0.61 (95%CI0.38-0.92) and 0.70 (95%CI0.45-1.08), respectively. The odds that that patients in the peripheral perfusion-targeted resuscitation arm had SOFA scores in the lower quartile at72-hours was 1.55 (95%confidence interval1.02-2.37). Peripheral perfusion-targeted resuscitation may result in lower mortality and faster resolution of organ dysfunction when compared to a lactated-targeted resuscitation strategy. This reanalysis can aid clinicians interpret the results of the trial. Clinical trial registration available at www.clinicaltrials.gov, ID:NCT0307871.